SGN-CD19A
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD19 |
Clinical data | |
ATC code | none |
Identifiers |
SGN-CD19A is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.[1] It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.[2]
Also known as Denintuzumab mafodotin[3] Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage.[4]
Clinical trials
The drug is currently in phase I clinical trials.[5] Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) are being presented at the ASH medical conference Dec 2015.[3]
Phase 2
A separate randomized phase 2 trial has started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL.[3]
A phase 2 clinical trial in front-line DLBCL is due to start in 2016.[3]
References
- ↑ http://www.seattlegenetics.com/sgn-cd19a
- ↑ http://finance.yahoo.com/news/seattle-genetics-presents-data-novel-150000223.html
- 1 2 3 4 Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015
- ↑ Statement on a nonproprietary name adopted by the USAN Council: Mafodotin
- ↑ Clinicaltrials.gov